Type 2 Diabetes: Hypoinsulinism, Hyperinsulinism, or Both? by Glaser, Benjamin
PLoS Medicine  |  www.plosmedicine.org 0619
Perspectives
April 2007  |  Volume 4  |  Issue 4  |  e148
T
ype 2 diabetes is a very common 
metabolic disease and its 
incidence is increasing rapidly 
worldwide [1]. Despite ﬁ  ve to six 
decades of extensive investigation, the 
basic physiologic defect responsible for 
type 2 diabetes mellitus (T2DM) is still 
not known. It is now well accepted that 
T2DM develops when the beta-cell is 
unable to supply the amount of insulin 
needed to maintain normal glucose 
levels [2]. But is the primary problem 
in the beta-cell itself? Or is the problem 
resistance to insulin action, which puts 
an abnormally high load on the beta-
cell, causing it to eventually fail? 
Epidemiologic studies have shown 
that genetic variation plays a very 
important part in determining the 
risk of developing diabetes. Currently 
available data suggest that for the vast 
majority of patients with T2DM, the 
genetic risk is determined by a variable 
combination of an unknown number 
of common genetic variants. Any of 
these variants alone is neither sufﬁ  cient 
nor necessary for diabetes to occur. 
Genetic analysis of T2DM has yielded 
only a few such genetic variants that 
are consistently associated with risk 
of disease. The study of monogenic 
disorders of glucose metabolism may 
shed light on potential mechanisms for 
the common form of T2DM.
Gene Mutations in Monogenic 
Diabetes 
To date, mutations in more than 
ten genes have been associated with 
different forms of monogenic diabetes. 
Maturity-onset diabetes of the young 
(MODY), an autosomal dominant 
disease with onset of diabetes typically 
before the age of 25 years, can be caused 
by mutations in more than six genes [3]. 
Neonatal diabetes, either transient or 
permanent, can be caused by mutations 
in at least four different genes as well as 
an imprinting disorder on chromosome 
6, the precise genetic mechanism 
of which has yet to be deﬁ  ned [4]. 
Common polymorphisms in some of 
these genes have been associated with 
increased risk of developing the more 
common form of polygenic T2DM. Most 
of the diabetes-related genes thus far 
identiﬁ  ed are expressed in beta-cells 
and the diabetes-associated mutations 
are thought to result in decreased beta-
cell function and inadequate insulin 
secretion. In an article published in 
PLoS Medicine, Pearson et al. report 
the birth weight of patients carrying 
a mutation in either of two closely 
related genes associated with the 
MODY syndrome, HNF4A and HNF1A, 
testing the hypothesis that the primary 
defect caused by these genes results in 
decreased insulin secretion [5].
The New Study
Birth weight is largely determined by 
fetal insulin secretion. Defective insulin 
secretion, such as is found in patients 
with neonatal diabetes, is associated 
with low birth weight [6]. In contrast, 
beta-cell defects that cause increased, 
unregulated insulin secretion 
as is found in hyperinsulinemic 
hypoglycemia of infancy are associated 
with macrosomia [7]. In addition, 
maternal factors inﬂ  uence fetal insulin 
secretion, and thus fetal growth, 
independently of speciﬁ  c genetic 
defects. Infants of diabetic mothers 
are exposed to increased glucose 
levels, which trigger increased fetal 
insulin secretion and macrosomia. 
Maternal malnutrition or placental 
insufﬁ  ciency results in decreased 
nutrient supply to the fetus, decreased 
fetal insulin secretion, and poor fetal 
growth. Interestingly, inappropriately 
low birth weight has been shown to be 
an important and highly signiﬁ  cant 
predictor of late-onset T2DM [8,9].
Since both HNF1A and HNF4A are 
associated with insulinopenic diabetes 
in young adults [10,11], it would 
be expected that affected newborns 
would be either small for gestational 
age, if the insulin secretion defect is 
evident during fetal life, or normal for 
gestational age, if the functional defect 
develops after birth. Furthermore, both 
HNF1A and HNF4A are thought to 
interact with each other, affecting each 
other’s expression level in the beta-cell 
[12–14]. Patients with diabetes caused 
by HNF1A and HNF4A mutations are 
phenotypically similar. It was expected, 
therefore, that defects in either gene 
would affect fetal growth in the same 
way. 
Surprisingly, Pearson et al. found 
that HNF4A mutations were associated 
with increased fetal weight in patients, 
whereas HNF1A mutations did not 
appear to affect fetal weight at all. 
This increase in fetal growth found in 
HNF4A mutation carriers appears to be 
a direct result of the fetal genotype and 
is not signiﬁ  cantly altered by maternal 
genotype. Similar weight gain was seen 
in fetuses carrying an HNF4A mutation, 
regardless of whether the mutation 
was inherited from the father or the 
mother. Furthermore, this mutation-
associated increase in birth weight is 
also seen when genetically discordant 
siblings are compared, negating 
the importance of intrauterine 
environment in determining fetal 
weight in this setting.
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To determine if this increase in 
birth weight is indeed caused by 
fetal hyperinsulinism, Pearson et 
al. reviewed patient records, and 
determined that eight out of 54 of the 
patients with HNF4A mutations had 
transient neonatal hypoglycemia, and 
in three of these elevated insulin levels 
were documented. In contrast, none 
of the normal siblings or the patients 
carrying an HNF1A gene mutation 
had neonatal hypoglycemia. This 
unexpected ﬁ  nding was conﬁ  rmed 
in a mouse model of beta-cell-
speciﬁ  c HNF4A depletion, which 
resulted in intrauterine and postnatal 
hyperinsulinism, with hypoglycemia in 
the postnatal period.
Implications of the Findings
Thus, it appears that MODY-
associated HNF4A mutations cause 
increased insulin secretion in the 
fetal and neonatal period, resulting in 
increased birth weight and neonatal 
hypoglycemia. Over time, the beta-cell 
function decreases, and insulinopenic 
diabetes develops, usually during the 
third decade of life. 
This is not the ﬁ  rst example of 
fetal hyperinsulinism developing 
into insulinopenic diabetes later 
in life. Huopio et al. report that 
dominant inactivating mutations in 
the sulfonylurea receptor (ABCC8), a 
major component of the beta-cell ATP-
regulated potassium channel, result in 
a similar phenotype: hyperinsulinemic 
hypoglycemia with macrosomia in 
infancy, decreased glucose-stimulated 
insulin secretion in adolescence and 
young adulthood, and frank diabetes 
during middle age [15,16]. The 
mechanism by which this occurs is 
not known, but it was proposed that 
chronic depolarization of the beta-cell 
plasma membrane results in abnormal 
opening of voltage-gated potassium 
channels, causing elevated intracellular 
calcium, which triggers apoptosis 
pathways. To determine if HNF4A 
mutations recapitulate this series of 
events by modulating the expression 
of either of the two genes that make 
up the KATP channel (ABCC8 and 
KCNJ11), Pearson et al. determined 
the expression of these genes in islets 
isolated from their mutant mice, 
but found no evidence of abnormal 
expression levels.
How then does this relate to the 
pathogenesis of polygenic T2DM? To 
deﬁ  ne the mechanism by which genetic 
variation predisposes to T2DM, two 
major scenarios have been proposed. 
In the ﬁ  rst scenario, decreased beta-
cell function, due to a primary beta-cell 
defect, predisposes to diabetes. In the 
presence of increased demand for 
insulin, such as obesity-related insulin 
resistance or physical inactivity, this 
relative inability to increase insulin 
production becomes more evident 
and the incidence of frank diabetes 
increases. In addition, it has been 
hypothesized that fetal nutritional 
deprivation “programs” the beta-cells so 
that they cannot adequately compensate 
for increased insulin demands later 
in life, providing an environmental 
mechanism with the same end result.
In the second scenario, there is 
a primary defect causing insulin 
resistance. However, only a fraction 
of patients with insulin resistance 
will develop frank diabetes. In the 
majority, the pancreas will compensate 
with increased insulin secretion, 
maintaining euglycemia. Thus, a 
second “defect” limiting the pancreas’s 
ability to compensate for insulin 
resistance is necessary for diabetes 
to occur. However, this may not be a 
distinct defect per se, but may simply 
represent the lower end of a normally 
distributed ability to increase beta-
cell mass or function in response to 
increased demand.
Genetic data that have accumulated 
over the last ten years suggest that 
T2DM is a genetically heterogeneous 
disease in which either or both of 
these two scenarios could be important 
in any given individual. The current 
study demonstrates that a third 
scenario, in which a primary beta-cell 
defect results in increased insulin 
secretion, and thus increased fetal 
growth, long-term beta-cell damage, 
and late-onset insulin deﬁ  ciency, may 
also be important in the pathogenesis 
of diabetes in some patients. It is not 
known how the same HNF4A mutation 
causes hyperinsulinism in the fetus 
and hypoinsulinism in the adult. Nor 
is it known why two very closely related 
genes, HNF4A and HNF1A, cause such 
different phenotypes. Genetic variants 
in the beta-cell speciﬁ  c (P2) promoter 
of HNF4A have been associated with 
polygenic T2DM. Could the scenario 
described by Pearson et al. be a 
common pathogenic mechanism for 
T2DM? Future studies are likely to 
address these important questions.  
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